Investigational drug · Phase 2
GR2301
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Vitiligo.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "GR2301"
First trial start
2026
Jun 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GR2301", any sponsor or status.
Conditions studied
As listed on its trial records.
- Vitiligo
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "GR2301" as an intervention, largest first.
- A Clinical Trial of Multiple Doses of GR2301 Injection in Participants With Vitiligo.Pivotal-lookingNot yet recruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT07930039 · 120 participants (planned) · Start Nov 2026 · Primary completion May 2028
Drug: GR2301 injection; Placebo · For: Vitiligo
- A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With VitiligoPivotal-lookingNot yet recruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT07647237 · 116 participants (planned) · Start Jun 2026 · Primary completion Jun 2028
Drug: GR2301 injection; Placebo · For: Vitiligo
- A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.Not yet recruiting
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT07647224 · 36 participants (planned) · Start Jun 2026 · Primary completion Jul 2027
Drug: GR2301 injection · For: Multiple Dose; Healthy Adult Participants
Sites: Beijing, China
Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
NCT07190716 · 36 participants (planned) · Start Oct 10, 2025 · Primary completion May 30, 2026
Drug: GR2301 injection · For: Single Ascending Dose; Healthy Subjects
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Vitiligo
- MH004Phase 32 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Vitiligo, Atopic Dermatitis (AD)
- TEV-53408Phase 32 trials
Teva · Vitiligo, Celiac Disease
- LY4005130Phase 22 trials
Eli Lilly · Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV)
- SHR0302BasePhase 22 trials
Jiangsu HengRui Medicine Co., Ltd. · Vitiligo, Non-segmental Vitiligo
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.